Menu
Search
|

Menu

Close
X

Exelixis Inc EXEL.OQ (NASDAQ Stock Exchange Global Select Market)

20.04 USD
-0.32 (-1.57%)
As of Jun 22
chart
Previous Close 20.36
Open 20.42
Volume 1,087,844
3m Avg Volume 930,998
Today’s High 20.56
Today’s Low 19.75
52 Week High 32.49
52 Week Low 18.50
Shares Outstanding (mil) 293.90
Market Capitalization (mil) 7,556.29
Forward P/E 136.33
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

Sell Hold Buy
1.88 Mean rating from 8 analysts

KEY STATS

Revenue (mm, USD)
FY18
212
FY17
452
FY16
191
FY15
37
EPS (USD)
FY18
0.369
FY17
0.494
FY16
-0.333
FY15
-0.793
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
136.33
32.74
Price to Sales (TTM)
vs sector
23.64
5.71
Price to Book (MRQ)
vs sector
50.85
5.37
Price to Cash Flow (TTM)
vs sector
127.42
23.32
Total Debt to Equity (MRQ)
vs sector
0.00
16.46
LT Debt to Equity (MRQ)
vs sector
0.00
12.19
Return on Investment (TTM)
vs sector
16.55
14.38
Return on Equity (TTM)
vs sector
--
16.08

EXECUTIVE LEADERSHIP

Stelios Papadopoulos
Independent Chairman of the Board, Co-Founder, Since 1998
Salary: --
Bonus: --
Michael Morrissey
President, Chief Executive Officer, Director, Since 2010
Salary: $841,154.00
Bonus: $800,000.00
Christopher Senner
Chief Financial Officer, Executive Vice President, Since 2015
Salary: $532,923.00
Bonus: $303,750.00
Gisela Schwab
President - Product Development and Medical Affairs, Chief Medical Officer, Since 2016
Salary: $591,186.00
Bonus: $375,000.00
Peter Lamb
Executive Vice President - Scientific Strategy, Chief Scientific Officer, Since 2016
Salary: $453,546.00
Bonus: $258,750.00

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

210 E Grand Ave
SOUTH SAN FRANCISCO   CA   94080-4811

Phone: +1650.8377000

Exelixis, Inc. is a biopharmaceutical company. The Company is focused on discovery, development and commercialization of new medicines to manage care and outcomes for people with cancer. The Company's cabozantinib product is an inhibitor of multiple tyrosine kinases, including MET, AXL, and VEGF receptors. The Company's CABOMETYX tablets are approved for previously treated advanced kidney cancer and COMETRIQ capsules are approved for progressive, metastatic medullary thyroid cancer. The third product, Cotellic, is a formulation of cobimetinib, a selective inhibitor of MEK is approved as part of a combination regimen to treat advanced melanoma. Both cabozantinib and cobimetinib have shown potential in a range of forms of cancer and are the subjects of broad clinical development programs. The Company's XL888 is a small molecule oral inhibitor of Heat Shock Protein 90 (HSP90), a molecular chaperone protein.

SPONSORED STORIES